At a glance
ClinicalIndex Comparison Record- ✓Patients with hematologic malignancies and non-malignancies who are candidates for matched sibling donor allogeneic bone marrow transplantation
- ✓Age under 55 years
- ✓Life expectancy of at least 12 weeks
- ✓Available histocompatible sibling donor who has been medically approved
- ✕Significant functional deficits in major organs that would interfere with successful transplant outcome
- ✕Evidence of active, deep-seated, life-threatening infections without known effective therapy (e.g., certain fungal species, HIV)
- ✕Hemoglobinopathy (sickle cell disease or thalassemia)
- ✕Greater than two leukemic episodes, active CNS/leukemic disease, or blast crisis in CML patients
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies
In Brief
A clinical study evaluating Granulocyte Colony Stimulating Factor for Hematologic Diseases and Hematologic Malignancies. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients with cancers or blood diseases, who have poor potential for a cure with standard treatment, will be able to participate in the study. Donors will receive the white cell growth hormone (G-CSF) as a shot (injection) in their arm once a day for three days before they donate their bone marrow cells. Total body irradiation and/or chemotherapy will be given first to prepare the patient's body for the infusion of new bone marrow cells from the donor. Two medicines (cyclosporine and methotrexate) will be used to prevent the new bone marrow cells (graft) from attacking the patient's body (host) (graft-versus-host disease; GVHD). Certain safety checkpoints were built into the study if unwanted/unexpected events were to occur. If the outcomes appear better than could be expected, this will provide a bridge to extend this current approach for other innovative therapies.
Study Details
Timeline
Interventions
Granulocyte Colony Stimulating Factor